JPMorgan Chase & Co. Cuts ICON Public (NASDAQ:ICLR) Price Target to $265.00

ICON Public (NASDAQ:ICLR) had its price target lowered by JPMorgan Chase & Co. from $280.00 to $265.00 in a report issued on Monday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical research company’s stock.

Several other equities analysts have also weighed in on ICLR. Barclays reduced their price objective on ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. William Blair reissued an “outperform” rating on shares of ICON Public in a report on Tuesday, January 14th. The Goldman Sachs Group reduced their price objective on ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a report on Friday, October 25th. Evercore ISI cut their price target on ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Robert W. Baird cut their price target on ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, ICON Public has a consensus rating of “Moderate Buy” and a consensus target price of $285.75.

ICON Public Price Performance

Shares of NASDAQ ICLR opened at $196.41 on Monday. The stock has a fifty day simple moving average of $208.20 and a two-hundred day simple moving average of $256.12. ICON Public has a 1-year low of $183.38 and a 1-year high of $347.72. The firm has a market cap of $16.20 billion, a price-to-earnings ratio of 21.90, a price-to-earnings-growth ratio of 1.79 and a beta of 1.19. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35.

Institutional Investors Weigh In On ICON Public

Hedge funds have recently made changes to their positions in the business. Sierra Ocean LLC bought a new stake in shares of ICON Public in the 4th quarter worth approximately $29,000. Park Place Capital Corp lifted its holdings in shares of ICON Public by 281.4% in the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after acquiring an additional 166 shares during the last quarter. Private Trust Co. NA lifted its holdings in shares of ICON Public by 48.8% in the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after acquiring an additional 82 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after acquiring an additional 169 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of ICON Public by 23.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after acquiring an additional 96 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.